Exploratory Study Analyzing the Urinary Peptidome of T2DM Patients Suggests Changes in ECM but Also Inflammatory and Metabolic Pathways Following GLP-1R Agonist Treatment

Type II diabetes mellitus (T2DM) accounts for approximately 90% of all diabetes mellitus cases in the world. Glucagon-like peptide-1 receptor (GLP-1R) agonists have established an increased capability to target directly or indirectly six core defects associated with T2DM, while the underlying molecu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lohia, Sonnal, Siwy, Justyna, Mavrogeorgis, Emmanouil, Eder, Susanne, Thöni, Stefanie, Mayer, Gert, Mischak, Harald, Vlahou, Antonia, Jankowski, Vera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488289/
https://www.ncbi.nlm.nih.gov/pubmed/37686344
http://dx.doi.org/10.3390/ijms241713540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488289/
https://www.ncbi.nlm.nih.gov/pubmed/37686344
http://dx.doi.org/10.3390/ijms241713540

Ejemplares similares